LAG3 Expression in Triple Negative Breast Cancer
Launched by SAMSUNG MEDICAL CENTER · Feb 6, 2024
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a specific protein called LAG-3, along with other immune checkpoint proteins, behaves in women with triple negative breast cancer who are receiving treatment before surgery, known as neoadjuvant chemotherapy. The goal is to understand if these proteins can impact how well the chemotherapy and immune therapies work together in fighting this type of breast cancer.
To be eligible for this trial, participants should be women who have been diagnosed with triple negative breast cancer and are planning to start neoadjuvant chemotherapy. However, women with HER2-positive or hormone receptor positive breast cancer are not eligible for this study. If you choose to participate, you can expect to receive treatment as part of the trial while contributing to important research that could help improve future treatments for triple negative breast cancer. The trial is currently recruiting participants, so there is an opportunity to get involved.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Planned neoadjuvant chemotherapy
- • Triple negative breast cancer
- Exclusion Criteria:
- • HER2-positive breast cancer
- • Hormone receptor positive breast cancer
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported